Contribution of genotypes in Prothrombin and Factor V Leiden to COVID-19 and disease severity in patients at high risk for hereditary thrombophilia.
Aslıhan KirazOzlem SezerAdem AlemdarSezin CanbekNilgun DumanAtıl BisginTulin CoraHatice Ilgın RuhiMahmut Cerkez ErgorenBilgen Bilge GeçkinliSebnem Ozemri SagHilmi Erdem GözdenOzlem OzZuhal Mert AltıntaşSinem YalcıntepeAdem KeskinAyşegül Yabacı TakŞeyma Aktaş PaskalUğur Fahri YürekliMercan DemirtasEmine Unal EvrenAbdullah HantaMüşerref BaşdemirciHuseyin Kaya SuerBurhan BaltaNadir KocakHalil Gürhan KarabulutHavva CobanogullarıEsra Arslan AteşSevcan Tuğ BozdoğanDamla EkerSadiye EkinciSüleyman NergizTimur TuncalıSerap YagbasanCeren AlavandaNuket Yurur KutlayHakan EvrenMurat ErdoğanSule AltınerTamer SanlidagGizem Akıncı GonenArzu VicdanNazan ErasHatice Koçak EkerOzgür BalasarGulten TuncelMunis DundarHakan GurkanSehime Gulsun TemelPublished in: Journal of medical virology (2023)
Overall, disease severity and development of thrombosis in COVID-19 are mainly affected by the variation within the FVL gene. Possible FVL mutation should be investigated in COVID-19 patients and appropriate treatment should be started earlier in FVL-positive patients. This article is protected by copyright. All rights reserved.